Skip to main content
TrimSoMoEverything GLP-1, in one place
← All medications

FDA-approved medication

Zepbound (tirzepatide)

Key facts

Last reviewed: 2026-11-04
  • •FDA label says "ZEPBOUND ® (tirzepatide) Injection, for subcutaneous use".
  • •FDA label says "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."
  • •FDA label says "The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved."
  • •FDA label says "Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly."

FDA-approved to reduce excess body weight and maintain weight reduction long term. Read the dose schedule and safety information, and check the official prescribing information. Confirm costs and coverage with your pharmacy, insurer, or the manufacturer.

tirzepatide · single-dose pen or single-dose vial; multi-dose vial or single-patient-use KwikPen · once weekly, subcutaneous

Active ingredient
tirzepatide
Dosage form (label)
Injection: single-dose pen or single-dose vial; multi-dose vial or single-patient-use KwikPen
Schedule (label)
Once weekly, subcutaneous
Strengths (label)
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Manufacturer
Eli Lilly and Company; marketed by Lilly USA, LLC (per label)

Brand names are trademarks of their respective owners; this site is not affiliated with them.

Abstract illustration of two intertwined molecule shapes beside a weekly desk calendar

FDA label

Zepbound dose steps (FDA label)

  1. 2.5 mg
    Weeks 1–4
    Starting dose
  2. 5 mg
    ≥ 4 weeks
    Dose step
  3. 7.5 mg
    ≥ 4 weeks
    Dose step
  4. 10 mg
    ≥ 4 weeks
    Dose step
  5. 12.5 mg
    ≥ 4 weeks
    Dose step
  6. 15 mg
    Label maximum
    Maximum dose
Per FDA label. Your prescriber sets your dose. The label lists 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term maintenance; 15 mg is the label maximum.

FDA label answers

Common questions about Zepbound

All answers are taken directly from the official FDA prescribing information (FDA Prescribing Information (DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 40, revised 08/2026)).

Who is Zepbound approved for?

FDA label says "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."

How often is Zepbound taken?

FDA label says "The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved."

What are the most common side effects listed on the label for Zepbound?

FDA label says "The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease."

Is there a boxed warning on the Zepbound label?

Yes. FDA label says "WARNING: RISK OF THYROID C-CELL TUMORS" — "In rats, tirzepatide causes thyroid C-cell tumors."

What are the recommended maintenance dosages for Zepbound?

FDA label says "Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly."

Patient Consultation & Copay Protocol

Next Steps: Evaluating Zepbound for Your Care Plan

Transition from drug facts to clinical action. Estimate potential out-of-pocket expenses, generate consultation questions, and verify eligibility.

All Decision Tools
Copay & Savings Card

Out-of-Pocket Expense Modeling

Estimate what you might pay each month based on manufacturer assistance terms and employer benefit design.

Covered Commercial: As low as $25 / month with manufacturer card (caps apply)
Uncovered Commercial: Approx. $550 – $650 / month via manufacturer savings card
Self-Pay Option: LillyDirect single-dose vials: $399 (2.5 mg) – $549 (5 mg) / month
Medicare: Standard Medicare Part D statutorily excludes chronic weight management
Clinical Readiness

Consultation & Lab Checklist

Arrive at your appointment prepared with essential baseline bloodwork requirements and contraindication screens.

Required Bloodwork: Comprehensive Metabolic Panel (kidney/liver), HbA1c, TSH, and lipid panel
Safety Screening: Screening for personal/family history of MTC, MEN 2, pancreatitis, and gallbladder disease.
Clinical Format: Includes 12 essential lab panels and formatted physician questions.
Eligibility & Providers

BMI Qualification & Directory

Verify your body mass index against official FDA prescribing label requirements and locate qualified clinicians.

FDA Label Threshold: BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidity

Editorial & Regulatory Standard: TrimSoMo is an independent, non-commercial healthcare information platform. Estimated out-of-pocket costs and savings card parameters reflect publicly published 2026 manufacturer program guidelines and do not guarantee individual insurance coverage or pharmacy dispensing prices. Prescriptions require clinical evaluation by a licensed physician.

Before Starting Zepbound

Gradual Dose Titration

Per the FDA label, doses start low and increase over several months to help reduce gastrointestinal side effects. Your clinician sets your schedule. Review post-marketing data in our GLP-1 side effects from FDA labels → FAERS reports do not prove cause.

Lifestyle & Nutrition Support

In clinical studies, medication was used together with a reduced-calorie diet and increased physical activity.

Long-Term Plan

Talk with your clinician before changing or stopping treatment.

Future Pharmacotherapy Outlook

Exploring non-injectable options?

Some oral GLP-1 medicines are FDA-approved and others are still in development. The list shows each medicine's status and source.

Oral GLP-1 medicines: see which are FDA-approved and which are still in development →